Targeted agents currently used for the treatment of CRC may be divided into three categories: anti-Vascular Endothelial Growth Factor (VEGF) such as bevacizumab, aflibercept, and ramucirumab; anti-Epidermal Growth Factor Receptor (EGFR) antibodies such as cetuximab and panitumumab; and finally multikinase inhibitors like regorafenib [9]. The gene discussed is VEGFA; the disease is colorectal carcinoma.